Viagra vs Alprostadil (Caverject/MUSE): Switching Between Them

How Sildenafil and Alprostadil Work Differently

Sildenafil blocks phosphodiesterase type 5 (PDE5), an enzyme that degrades cyclic GMP in corpus cavernosum smooth muscle. By preserving cyclic GMP signaling initiated during sexual arousal, sildenafil amplifies the nitric oxide pathway that produces penile erection. This mechanism requires intact nerve signaling and at least partial endothelial function to generate nitric oxide in the first place.

Alprostadil takes a different route entirely. As a synthetic prostaglandin E1, it binds EP2 and EP4 receptors on cavernosal smooth muscle cells, directly activating adenylyl cyclase and raising intracellular cyclic AMP 1. This cyclic AMP elevation relaxes smooth muscle and increases arterial inflow without requiring sexual stimulation or intact nerve pathways. That distinction matters. Men with severe neurogenic ED after radical prostatectomy or spinal cord injury, where the nitric oxide cascade is disrupted, can still respond to alprostadil even when sildenafil fails.

The Goldstein et al. key trial (N=532) established sildenafil's efficacy, with 69% of all attempts at intercourse succeeding on the 100 mg dose compared to 22% on placebo 2. The Linet and Ogrinc trial (N=296) demonstrated that intracavernosal alprostadil produced erections sufficient for intercourse in 70% of injections across a dose range of 2.5 to 20 mcg 1. These numbers come from different populations and trial designs, so a direct head-to-head comparison is not valid from these data alone.

Who Should Consider Switching from Viagra to Alprostadil

The short answer: men who have given sildenafil (and often other PDE5 inhibitors) a genuine trial and still cannot achieve adequate erections. Genuine trial means at least 6-8 attempts on maximal dose with proper timing and sexual stimulation.

The American Urological Association (AUA) guidelines position PDE5 inhibitors as first-line pharmacotherapy for ED and intracavernosal injection as second-line for PDE5 non-responders 3. Between 30% and 35% of men do not respond adequately to any PDE5 inhibitor. The reasons vary: severe vascular disease limiting nitric oxide generation, post-prostatectomy cavernous nerve damage, uncontrolled diabetes with autonomic neuropathy, or psychological factors that prevent sufficient arousal to trigger the PDE5-dependent pathway.

Men taking organic nitrates for angina represent another clear switching population. Sildenafil is absolutely contraindicated with nitrates due to the risk of severe hypotension 4. Alprostadil carries no such contraindication because its vasodilatory action is local rather than systemic. For nitrate-dependent patients with ED, alprostadil injection or MUSE may be the only pharmacologic option outside of a penile prosthesis.

A third group includes men who experience intolerable side effects from sildenafil. Headache occurs in 16% and flushing in 10% of sildenafil users at the 100 mg dose 2. Visual disturbances (blue-tinged vision from PDE6 cross-reactivity) affect about 3%. When these side effects are persistent enough to discourage use, alprostadil bypasses the systemic PDE5 pathway entirely.

Who Should Consider Switching from Alprostadil to Viagra

Some men start on alprostadil, often after post-surgical ED, and later regain enough nerve function to respond to oral therapy. This is common after nerve-sparing radical prostatectomy. Cavernous nerve recovery can continue for 18 to 24 months postoperatively 5, and men initially dependent on injections may find that sildenafil becomes effective as nerves regenerate.

Injection fatigue is real. A study following intracavernosal injection therapy over 5 years found dropout rates of 40-68%, with penile pain and the psychological burden of self-injection cited as primary reasons 6. Men who dread the needle or who experience recurring injection-site pain are reasonable candidates for a trial of oral PDE5 inhibitors, assuming no contraindication exists.

Partner preference also plays a role. The injection-erection-intercourse sequence lacks spontaneity, and some couples prefer the less medicalized feel of an oral tablet taken 30 to 60 minutes before intimacy. This is not a trivial consideration. Adherence drops when the treatment disrupts the sexual experience, regardless of how well it works mechanically.

Timing and Safety When Switching

There is no required washout period between sildenafil and alprostadil. They work through independent signaling cascades (cyclic GMP vs. cyclic AMP), so pharmacologic interaction is minimal. A man can stop sildenafil and use alprostadil at his next sexual encounter, or vice versa.

One timing caution applies. Do not use both drugs on the same day without physician guidance. While the mechanisms differ, both produce penile smooth muscle relaxation, and combined use raises the theoretical risk of prolonged erection or priapism. Case reports document priapism when PDE5 inhibitors were used concurrently with intracavernosal alprostadil 7. The safe practice is to choose one drug per sexual encounter.

When switching to Caverject, the first injection should always be administered in a clinical setting. The initial dose is typically 2.5 mcg for neurogenic ED or 10 mcg for vasculogenic ED 1. Office titration allows the clinician to assess response duration. Any erection lasting longer than 4 hours requires emergency treatment with phenylephrine injection.

When switching to MUSE (intraurethral alprostadil), the standard starting dose is 250 mcg, with titration up to 1,000 mcg. MUSE is less effective than injection. A large comparative trial showed 43% of MUSE users achieved erections sufficient for intercourse compared to 70% with intracavernosal injection 8.

When switching to sildenafil from alprostadil, start at 50 mg, taken 30 to 60 minutes before sexual activity on an empty stomach. The dose can be adjusted to 25 mg or 100 mg based on response and tolerability 2.

Efficacy Comparison Across Populations

No large randomized trial has directly compared sildenafil head-to-head against alprostadil injection. The evidence base consists of separate trials in partially overlapping populations, crossover studies, and meta-analyses.

A crossover study by Shabsigh et al. (N=55) found that among men who had failed sildenafil, 85% achieved erections sufficient for penetration with intracavernosal alprostadil 9. This suggests alprostadil rescues a large proportion of PDE5 non-responders. The reverse scenario, sildenafil rescuing alprostadil non-responders, has less published data, in part because alprostadil failure often indicates severe vascular compromise where oral agents are unlikely to help.

In diabetic ED specifically, sildenafil efficacy drops to approximately 56% compared to its 65-70% rate in general populations 10. Alprostadil injection maintains roughly 65-70% efficacy in diabetic men 1, giving it an edge in this subgroup. The Endocrine Society's clinical practice guidelines recommend PDE5 inhibitors first for diabetic ED, with intracavernosal injection as the next step 11.

After radical prostatectomy, the picture depends on surgical technique. With bilateral nerve-sparing surgery, sildenafil achieves adequate erections in approximately 43% of men at 12 months 5. Without nerve sparing, that figure falls below 15%. Intracavernosal alprostadil works regardless of nerve status because it directly activates smooth muscle relaxation, achieving response rates of 60-70% even after non-nerve-sparing prostatectomy.

Side Effects and Risk Profiles

Sildenafil's most common adverse effects are headache (16%), flushing (10%), dyspepsia (7%), nasal congestion (4%), and transient visual changes (3%) 2. These are systemic because the drug circulates throughout the body. Serious cardiovascular events are rare and are typically associated with contraindicated nitrate co-use rather than sildenafil itself. The FDA label carries a black-box contraindication for concurrent organic nitrate use 12.

Alprostadil's side-effect profile is local. Penile pain at the injection site occurs in 30-50% of Caverject users, though severity is typically mild and diminishes with continued use 1. Prolonged erection (4-6 hours) occurs in about 5% of injections, and priapism (over 6 hours) in about 1% 6. Penile fibrosis or Peyronie-like plaques develop in 2-12% of long-term injection users, depending on frequency and technique. MUSE produces urethral burning in about 33% of users and has lower priapism risk than injection.

The practical safety summary: sildenafil is systemically safer but carries a hard contraindication with nitrates. Alprostadil is locally riskier (pain, fibrosis, priapism) but has no systemic cardiovascular contraindications.

Cost and Access Considerations

Generic sildenafil transformed the economics of ED treatment after Viagra's patent expiration. A 100 mg tablet costs $1-8 at most pharmacies, with GoodRx-type discount programs sometimes pushing the per-dose cost below $1. Insurance coverage varies, with many plans limiting quantities to 6-8 tablets per month.

Alprostadil remains expensive. Brand Caverject Impulse costs $50-75 per injection at retail. Generic alprostadil for injection is available at $30-50 per dose. MUSE suppositories run $25-60 each. Insurance coverage for alprostadil is more consistent than for sildenafil because it is often classified as a medical treatment rather than a lifestyle drug, particularly in post-surgical or nitrate-dependent populations.

Compounded alprostadil, often combined with papaverine and phentolamine in "trimix" formulations, reduces per-injection cost to $3-10 through specialty compounding pharmacies 13. Trimix is the most commonly prescribed intracavernosal combination in clinical practice and may be the practical choice for men who need long-term injection therapy.

Combination and Sequential Therapy

Some clinicians prescribe sildenafil and alprostadil together for refractory ED, but this approach requires careful dosing. A study by McMahon et al. found that adding sildenafil 25-50 mg to low-dose intracavernosal alprostadil improved rigidity in men who responded poorly to either agent alone 14. The protocol involved using a reduced alprostadil dose (5-10 mcg instead of 20 mcg) with sildenafil taken orally 30 minutes prior to injection.

This combination carries elevated priapism risk and should only be used under close medical supervision with the patient educated on emergency priapism management. It is not a standard recommendation in current AUA or EAU guidelines but is practiced in specialized sexual medicine clinics.

Sequential therapy, moving between the two drugs over time based on clinical response, represents a more common and safer strategy. A man might use sildenafil for years, switch to Caverject when oral therapy loses efficacy, and potentially return to oral agents if underlying conditions improve.

Making the Decision: A Clinical Framework

The choice between sildenafil and alprostadil depends on four factors: underlying ED etiology, nitrate use, patient preference regarding route of administration, and cost sensitivity.

Start with sildenafil (or another PDE5 inhibitor) if the patient has no nitrate contraindication and has not previously failed oral therapy. This is standard of care per the AUA, EAU, and ISSM guidelines 3.

Switch to alprostadil injection if: the patient has failed adequate trials of at least two PDE5 inhibitors, uses organic nitrates, or has neurogenic ED unresponsive to oral therapy. Begin with in-office dose titration using Caverject 10 mcg for vasculogenic ED.

Consider MUSE as an intermediate step for men who want to avoid injection but have failed oral therapy, accepting the trade-off of lower efficacy (43% vs. 70% for injection) 8.

The starting dose for men switching from sildenafil to Caverject is 10 mcg intracavernosal, titrated in-office in 5 mcg increments to a maximum of 40 mcg per injection, with no more than 3 injections per week and at least 24 hours between uses 1.